The present invention relates to epidermal growth factor (EGF) producing lactic acid bacteria and their use to increase intestinal villi height and to promote gut absorption. In particular, the invention relates to EGF producing Lactococcus lactis and Lactobacillus casei. The organisms may be especially...http://www.google.com/patents/US7601799?utm_source=gb-gplus-sharePatent US7601799 - Methods and means to promote gut absorption

The present invention relates to epidermal growth factor (EGF) producing lactic acid bacteria and their use to increase intestinal villi height and to promote gut absorption. In particular, the invention relates to EGF producing Lactococcus lactis and Lactobacillus casei. The organisms may be especially useful to treat Short Bowel Syndrome.

Images(3)

Claims(3)

1. A method of enhancing villus growth in a subject, said method comprising:

This application is a continuation of PCT International Patent Application No. PCT/EP2003/050424, filed on Jun. 19, 2003, designating the United States of America, and published, in English, as PCT International Publication No. WO 2004/01020 A2 on Dec. 31, 2003, the contents of the entirety of which is incorporated by this reference.

TECHNICAL FIELD

The present invention relates generally to biotechnology, and, more particularly, to epidermal growth factor (EGF) producing lactic acid bacteria and their use to increase intestinal villi height and to promote gut absorption. In particular, the invention relates to EGF producing Lactococcus lactis and Lactobacillus casei. These organisms may be especially useful to treat Short Bowel Syndrome.

BACKGROUND

The efficiency of gut absorption is essential for good food conversion. Gut adsorption is largely determined by the gut surface, which is a function, amongst others, of the length of the gut and the height of the villi. In cases where an operative removal of a part of the gut is necessary, as in the case of cancer or Crohn's disease, this may result in decreased gut adsorption, resulting in insufficient food conversion and a shortage of nutrients, dehydration and even potentially lethal metabolic changes. These syndromes caused by the extensive resection of the small intestine are known as “Short Bowel Syndrome.”

Several methods have been proposed to improve the post-operational adaptation of, and to enhance, the gut absorption in patients with Short Bowel Syndrome. U.S. Pat. No. 5,288,703 discloses that both growth hormone and insulin-like growth factor have a positive effect on gut absorption in mammals. This positive effect can be enhanced by the administration of glutamine or a glutamine equivalent. Administration of glutamine and growth hormone results in an increase of the villi length (Gu et al., 2001; Zhou et al., 2001). U.S. Pat. No. 5,972,887 demonstrated a reversal of the reduced intestinal mucosal mass and absorptive function in patients by the administration of low doses of exogenous Hepatocyte Growth Factor. In addition, the glucagon-like peptides GLP-1 and GLP-2 have been used with positive results. Studies on laboratory animals (Scott et al., 1998), as well as on humans (Jeppesen et al., 2001), showed a positive correlation between an increase in concentration of GLP-2 and an improvement of the intestinal adaptation. Short Bowel patients, from whom the ileum has been removed, show a decrease in food-induced secretion of GLP-2 (Jeppesen et al., 1999). Those patients, especially, can be treated successfully with GLP-2. It has been shown that leptin also has a positive effect on intestinal adaptation in a rat model (Pearson et al., 2001).

A lot of interest has been paid to the effect of Epidermal Growth Factor (EGF, urogastron). EGF is a relatively acid stable hormone that is produced in the salivary and the Brunner's glands. It is found in a wide variety of external secretions, as well as in blood and amniotic fluid (Marti et al., 1989). The molecular weight of mature human EGF is 6.2 kDa (Carpenter et al., 1991). EGF is phylogenetically strongly conserved and is strongly cross-reactive between different species.

It is known that EGF increases the absorption of H2O, Na+, Cl− and glucose in a rabbit model (Opleta-Madsen et al., 1991). Moreover, EGF is stimulating the elongation of the villi. This results in an increase of the apical surface and a general increase in absorption of nutrients (Hardin et al., 1999). Absorption of carbohydrates is further facilitated by the EGF-stimulated secretion of pancreatic amylase (Piiper et al., 1994).

EGF-mediated effects after intestinal resection are strongly dose dependent; up to a certain limit, the adaptation increases with increasing doses. In intestinal studies, the normal dose is situated between 30 and 300 μg/kg body weight/day. Systemic, as well as enteral, applications seem effective. However, systemic application may be unwanted for possible side effects; several neoplasmas do have EGF receptors and a general increase in EGF concentration in the blood might stimulate the formation of tumors. Enteral application of EGF, however, is less efficient as pepsin can process mature EGF into a truncated form that has only 25% of the initial biological activity (Playford et al., 1995).

DISCLOSURE OF THE INVENTION

Surprisingly, demonstrated is that EGF can be delivered in situ by recombinant lactic acid bacteria producing EGF. Efficient production and secretion of EGF by lactic acid bacteria is not evident, and needs optimization of the coding sequence. Moreover, it cannot be predicted that the lactic acid bacteria sufficiently survive the passage through the stomach to produce the appropriate amount of EGF to stimulate growth of the villi, to promote nutrient absorption and to treat the Short Bowel Syndrome.

It is a first aspect of the invention to provide an EGF producing lactic acid bacterium. Preferably, the lactic acid bacterium is secreting the EGF produced in the growth environment. Preferably, the lactic acid bacterium is a Lactococcus lactis or a Lactobacillus casei. Even more preferably, the lactic acid bacterium comprises SEQ ID NO:1 and/or SEQ ID NO:3 of the accompanying and incorporated herein SEQUENCE LISTING. A preferred embodiment is an EGF producing Lactococcus lactis comprising SEQ ID NO:3. Another preferred embodiment is an EGF producing Lactobacillus caseicomprising SEQ ID NO:3.

Another aspect of the invention is the use of an EGF producing lactic acid bacterium according to the invention to promote gut absorption. Methods to measure gut absorption are known to the person skilled in the art. Still another aspect of the invention is the use of an EGF producing lactic acid bacterium according to the invention to treat the Short Bowel Syndrome. Preferably, the lactic acid bacterium according to the invention is applied orally; it may be treated by any treatment known to the person skilled in the art to improve its survival during the passage of the intestinal system. As a non-limiting example, it may be freeze-dried or spray dried and/or encapsulated in a suitable recipient so that the bacteria are only released in the small intestine. Encapsulation and treatments for delivery in the small intestine have been described, amongst others in U.S. Pat. No. 5,972,685, International Publication Nos. WO0018377 and WO0022909.

The lactic acid bacterium, according to the invention, may be combined with other compounds, having a positive effect on gut absorption and/or enhancing the positive effect of EGF. As a non-limited example, glutamine can be used in combination of the lactic acid bacterium according to the invention.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1: Outline of the construction of pT1hEGF. The construction of pT1mEGF is carried out in a similar way.

FIG. 2: Expression of mEGF (A) and hEGF (B) in L. lactis and L. casei. Supernatant of the cultures as indicated is separated on a 20% polyacrylamide gel and the proteins are detected using a Western blot.

FIG. 3: Average villus length of the mice treated with either Lactococcus lactis or Lactobacillus casei, transformed with the empty vector pT1NX (pT1NX), with the vector pT1mEGF, expressing murine EGF (mEGF) or with the vector pT1hEGF expressing human EGF (hEGF). Medium BM9 treated mice are used as additional negative control (BM9).

Example 1Optimizing the EGF Coding Sequence for Expression in Lactococcus

Both the murine as well as the human EGF (accession number X04571 for hEGF and NM 010113 for mEGF) are available in the public databases at the National Center for Biotechnology Information (accession number X04571 for hEGF and NM—010113 for mEGF). The coding sequences were adapted to optimize the expression in Lactococcus. On the base of these sequences, primer sets were designed to assemble the optimized coding sequences of both hEGF and mEGF. At the 3′ end of the coding sequence, a SpeI restriction site was introduced. The primers are shown in Table 1 (hEGF) and Table 2 (m EGF).

TABLE 1

oligos used for assembly of hEGF, and the amount available

Sense

HEGF01

AACTCAGATTCAGAATGTCCACTTTCACACGATGGTTACT

33.3 nmol

(SEQ ID NO:5)

HEGF02

GTTTGCACGATGGTGTTTGTATGTACATCGAAGCTCTTGA

34.8 nmol

(SEQ ID NO:6)

HEGF03

TAAATACGCTTGTAACTGTGTTGTTGGTTACATCGGTGAA

26.9 nmol

(SEQ ID NO:7)

HEGF04

CGTTGTCAATACCGTGATTTGAAATGGTGGGAACTTCGTT

28.8 nmol

(SEQ ID NO:8)

HEGF05

AACTAGTCTGCAGAATCTAG

29.7 nmol

(SEQ ID NO:9)

Antisense

HEGF06

CTAGATTCTGCAGACTAGTTAACGAAGTTCCCACCATTTC

31.1 nmol

(SEQ ID NO:10)

HEGF07

AAATCACGGTATTGACAACGTTCACCGATGTAACCAACAA

22.5 nmol

(SEQ ID NO:11)

HEGF08

CACAGTTACAAGCGTATTTATCAAGAGCTTCGATGTACAT

23.6 nmol

(SEQ ID NO:12)

HEGF09

ACAAACACCATCGTGCAAACAGTAACCATCGTGTGAAAGT

28.4 nmol

(SEQ ID NO:13)

HEGF10

GGACATTCTGAATCTGAGTT

37.8 nmol

(SEQ ID NO:14)

TABLE 2

oligos used for assembly of mEGF, and the amount available

Sense

MEGF01

AACTCATACCCAGGTTGTCCATCATCATACGATGGTTACT

29.7 nmol

(SEQ ID NO:15)

MEGF02

GTTTGAACGGTGGTGTTTGTATGCACATCGAATCACTTGA

28.0 nmol

(SEQ ID NO:16)

MEGF03

TTCATACACTTGTAACTGTGTTATCGGTTACTCAGGTGAT

20.0 nmol

(SEQ ID NO:17)

MEGF04

CGTTGTCAAACTCGTGATTTGCGTTGGTGGGAACTTCGTT

25.5 nmol

(SEQ ID NO:18)

MEGF05

AACTAGTCTGCAGAATCTAG

29.7 nmol

(SEQ ID NO:19)

Antisense

MEGF06

CTAGATTCTGCAGACTAGTTAACGAAGTTCCCACCAACGC

33.4 nmol

(SEQ ID NO:20)

MEGF07

AAATCACGAGTTTGACAACGATCACCTGAGTAACCGATAA

30.2 nmol

(SEQ ID NO:21)

MEGF08

CACAGTTACAAGTGTATGAATCAAGTGATTCGATGTGCAT

27.3 nmol

(SEQ ID NO:22)

MEGF09

ACAAACACCACCGTTCAAACAGTAACCATCGTATGATGAT

26.2 nmol

(SEQ ID NO:23)

MEGF10

GGACAACCTGGGTATGAGTT

40.3 nmol

(SEQ ID NO:24)

The oligonucleotides were dissolved in water at a concentration of 100 μM, and used in a 10 times diluted concentration.

In the case of hEGF, HEGF01 and HEGF06 were used as primer; for mEGF, MEGF01 and MEGF06 were used. For hEGF, the same temperature schedule was used as for the first step. In the case of mEGF, the hybridization step was carried out at 52° C. in stead of 48° C.

After the assembly, the size of the optimized gene fragments was confirmed on a 2% agarose gel.

Example 2Construction of pT1hEGF and pT1mEGF and transformation into Lactococcus lactis

SpeI cut assembled EGF (both for hEGF and mEGF) is ligated into a NaeI and SpeI digested pT1NX (Steidler et al., 1995), resulting in pT1hEGF and pT1mEGF. A schematic overview of the construction of pT1hEGF is shown in FIG. 1. Plasmids are transformed into competent cells of L. lactis by electroporation. 50 μl of cells are electroporated in a precooled cuvet of 2 mm, at 25 μF, 2.5 kV and 400 Ω (Bio-Rad electroporator). L. lactis is made competent by growing a 1/100 dilution of a saturated culture, in 200 ml GM17 with 2.5% glycine, until an OD600 of 0.5 (Wells et al., 1993). After electroporation, 1 ml of recuperation medium is added, and the cells are incubated for 1.5 hour at 28° C. Cells are plated on GM17 solid medium, comprising 5 μg/ml erythromycin.

For the transformation of L. casei, plasmid is isolated from L. lactis on a Qiagen-tip 100, according to the instructions of the manufacturer. The DNA is transformed into competent L. casei cells. L. casei cells are made competent by growing a 1/50 dilution of an overnight culture in 50 ml MRS (Oxoid LTD., Basingstoke, Hampshire, England) with 1% glycine at 37° C., untill an OD600 of 0.6. The cells are harvested and washed twice with 10 ml 5 mM Na3PO4 pH 7.4, 1 mM MgCl2, and resuspended in 500 μl electroporation buffer (0.3 M sucrose, 5 mM Na3PO4 pH 7.4, 1 mM MgCl2). 10 μl of DNA is added to 50 μl of competent cells and the electroporation is carried out in a BioRad electroporator. After electroporation, 450 μl MRS is added and the cells are incubated for two hours at 37° C. Cells are plated on MRS agar with 5 μg/ml erythromycin. The presence of the plasmid is confirmed using PCR.

Example 3Expression of EGF in L. lactis and L. casei

The transformed L. lactis strains MG1363 [pT1NX], MG1363 [pT1mEGF] and MG1363 [pT1hEGF] are pitched in 5 ml GM17 comprising 5 μg/ml erythromycin, and grown overnight at 30° C. This preculture is diluted 1/100 in 5 ml GM17 with erythromycin, and incubated for three hours at 28° C. The culture is centrifuged and resuspended in BM9 expression medium, and incubated overnight at 28° C. The transformed L. casei strains are grown under similar conditions, but using MRS as preculture, and BM9 as expression medium.

To the culture supernatant, 1/10 volume sodium desoxycholate is added, and the mixture is kept on ice for 10 minutes. 1/10 of volume 100% TCA is added and the mixture is incubated on ice for 15 minutes. After centrifugation, the pellet is dissolved in 50 μl H2O and 50 μl 1 M Tris-HCl pH 9.5. The proteins are analyzed on a 20% Laemmli protein gel. Detection is carried out using a Western blot, with mouse polyclonal anti hEGF and rabbit anti mEGF as primary antibodies. Alkaline phosphatase labeled anti-mouse and anti-rabbit secondary antibodies were from Southern Biotechnology (Birmingham, USA). The results are summarized in FIG. 2.

In order to assess the effect of the transformed lactic acid bacteria and the growth of the villi and the gut adsorption, seven groups of Balb/c mice (IFFA CREDO CR Broekman/Sulzfield) were treated either with a mEGF or hEGF expressing lactic acid bacterium strain. L. lactis and L. casei transformed with an empty vector pT1NX, or with BM9 medium was given to mice as a negative control.

600 μl of L. casei is pitched in 15 ml MRS with 10 μg/ml erythromycin. In the case of L. lactis, GM17 is used instead of MRS, and only 5 μg/ml erythromycin is used for selection. L. casei is incubated overnight at 37° C., for L. lactis, 30° C. is used. The overnight culture is harvested by centrifugation, and the pellet is resuspended in 1.5 ml BM9 expression medium. 100 μl of this solution is supplied daily, for a period of four weeks. At the end of the experiment, the mice are sacrificed and the intestine is isolated. The tissue is fixated in buffered formaldehyde and thin sections are colored using hematoxylin and eosin G, for microscopic analysis of the villi. The length of the villi is measured at several points to obtain a representative average. All sections were taken from the terminal ileum.

The results are summarized in FIG. 3. L. casei [pT1hEGF], especially, has a positive effect on villus growth and should promote gut absorption.

Orally administering eubacterium coprostonaligenes into the small intestine of hypercholesterolemic mammals; reduces absorption of dietary and endogenous cholesterol by converting cholesterol to coprostanol

Delivering antigens or biologically active polypeptides to a subject in need of same by administering to the subject a non-invasive or non-pathogenic bacterium which expresses the antigens or polypeptides